Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

A-49 Use of Ribavirin in Blood Coagulation Disorder


技術應用

ΓùÅ To reduce the dosage of procoagulants for blood coagulation disorder patients. .ΓùÅ Could be used as a coagulator during surgical operations to reduce a bleed. .ΓùÅ Could be used as a coagulator to prevent and stop bleeds caused by some diseases.


詳細技術說明

Ribavirin has already been approved by the FDA and is regularly used for the treatment of chronic Hepatitis C. Researchers also discovered the Ribavirin application induced more mRNA expression of coagulation factor VII (F-VII, Proconvertin) in human hepatic parenchymal cell line. In addition, they discovered the concentration of other coagulation factors such as Fibrinogen (F-I), Prothrombin (F-II) and Proaccelerin (F-V) increased during this therapy. These increments of coagulation factors are thought to cause the decrement of procoagulants dosage during the treatment of Hepatitis C. The acceleration or improvement of blood coagulation by Ribavirin could help patients reduce their daily procoagulants applications. .


附加資料

Inventor: HONDA, Takashi | TAKAMATSU, Junki | TOYODA, Hidenori | YAMAMOTO, Koji | GOTO, Hidemi
Priority Number: WO2007099652A1
IPC Current: A61K00317056 | A61P000704 | C07H0019052 | C07H0019056
Assignee Applicant: National University Corporation Nagoya University
Title: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BLOOD CLOTTING DISORDER | COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU TROUBLE DE LA COAGULATION
Usefulness: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BLOOD CLOTTING DISORDER | COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU TROUBLE DE LA COAGULATION
Summary: For preventing/treating blood coagulation disorder, bleeding which is associated with deficiency of coagulation factor VII, viral infections disease caused by hepatitis C virus (HCV) or human immunodeficiency virus (HIV), and hemophilia A and B (all claimed).
Novelty: Pharmaceutical composition useful for treating blood coagulation disorder associated with factor VII deficiency, preferably hemophilia, comprises purine nucleoside derivative


主要類別

診斷/治療


細分類別

人類免疫缺陷病毒


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版